Genetics in Non-response to Anti-VEGF Treatment in Exudative AMD (RESPONSE)

University of Cologne

Status and phase: Unknown; Phase 4

Conditions: Macular Degeneration

Treatments: Drug: Ranibizumab

Study type: Interventional

Funder types: Other

Identifiers

NCT01213667

RESPONSE2010

Details and patient eligibility

About

To assess genetic features and intraocular cytokine profiles of non-responders to anti-VEGF treatment of exudative age-related macular degeneration. Also to assess necessity and frequency of pro re nate medical re-treatment.

Enrollment: 110 estimated patients

Sex: All

Ages: 60+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• active subfoveal CNV related to exudative age-related macular degeneration (all subforms)
• age > 60 years
• visual acuity > 20/400
• no previous treatment for AMD

Exclusion criteria

• any previous AMD therapy
• other CNV types (myopic, parapapillary)
• contraindication for ranibizumab treatment
• prior study participation for AMD
• pregnancy / premenopausal women

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

110 participants in 1 patient group

ranibizumab as needed

Other group

Treatment:

Drug: Ranibizumab